A82846 antibiotics
AssigneeEli Lilly and Company
InventorsRobert L. Hamill, James A. Mabe, David F. Mahoney, Walter M. Nakatsukasa, Raymond C. Yao
Life of this patent
Estimating the term…
Abstract
New glycopeptide antibiotic A82846, comprising A82846A, A82846B and A82846C, is produced by Nocardia orientalis strains NRRL 18098, NRRL 18099 and NRRL 18100. The A82846 antibiotics have activity against Gram-positive bacteria comparable to that of vancomycin.
Claims10
A process for producing antibiotic A82846 which comprises cultivating Nocardia orientalis NRRL 18098 or NRRL 18099, or an A82846-producing mutant or variant thereof, in a culture medium containing assimilable sources of carbon, nitrogen, and inorganic salts under submerged aerobic fermentation conditions until antibiotic A82846 is produced.
A process for producing antibiotic A82846 which comprises cultivating Nocardia orientalis NRRL 18100, or an A82846-producing mutant or variant thereof, in a culture medium containing assimilable sources of carbon, nitrogen, and inorganic salts under submerged aerobic fermentation conditions until antibiotic A82846 is produced.
A biologically purified culture of Nocardia orientalis strains NRRL 18098 or NRRL 18099 or an A82846-producing mutant or variant of said strains.
A biologically purified culture of Nocardia orientalis NRRL 18100 or an A82846-producing mutant or variant of NRRL 18100.
Dependencies are inferred from the claim text.